LUGPA Annual Meeting

Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.

Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.

Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.

BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.

Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.

Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.

Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.

Patient priorities and practice logistics should guide therapy selection in BCG-unresponsive NMIBC, according to Katie S. Murray, DO, MS, FACS.

Biomarkers including HRR mutations, PTEN loss, and PSMA expression can guide triplet selection in mHSPC, according to Benjamin Garmezy, MD.

William Huang, MD, discusses histotripsy for renal tumors, the #HOPE4KIDNEY trial, and the technology’s potential to preserve kidney function.

Systemic therapy now anchors MIBC care and expands bladder preservation options, according to Joshua J. Meeks, MD, PhD.

BCG optimization should precede checkpoint inhibitor intensification in BCG-naive high-risk NMIBC, according to Tom Jayram, MD.

The 2026 LUGPA Annual Meeting will tackle policy, artificial intelligence, and practice growth, according to Benjamin H. Lowentritt, MD, FACS.

Independent urology faces stagnant Medicare pay, rising costs, prior auth burden, and consolidation pressure, Celeste Kirschner, CAE, MHSA, says.

LUGPA CEO Celeste Kirschner, CAE, MHSA, outlines the association's top 2027 priorities: fee schedule reform, site-neutral payments, prior authorization, and practice consolidation.

Matthew A. Love, MD, discusses key efficiency and safety considerations for the SURE procedure.

Celeste Kirschner, CAE, MHSA, outlines the most pressing challenges facing independent urology practices today.

Ravi D. Chauhan, MD, FACS, outlines the practical considerations for administering nadofaragene in clinical practice.

"I think MRI has really been perhaps the most transformative development in the realm of prostate cancer screening since I came into the field," says Stacy Loeb, MD, MSc, PhD (Hon.

"It's been a very exciting time for the radioligand space," says J. Travis Mendel, MD.

Jonathan Henderson, MD, recaps his LUGPA 2025 session, “Lessons Learned: Avoiding Pitfalls in Urology Practice Management.”

Mobley also shares her treatment approach to BPH and explains the challenges of treating OAB.

Ronney Abaza, MD, predicts the transformative impact that AI will have in robotic surgery.

"I'm very excited to bring this therapy to our patients in the Philadelphia area and to be able to offer it at MidLantic," says David Cahn, DO, MBS, FACOS.

In determining the best treatment, urologist Arpeet Shah, MD, stresses the importance of thorough diagnostics.

Brooke Edwards, MD, highlights key takeaways from her LUGPA 2025 session, "Transforming your ASC."

"For me and the patients, [nadofaragene firadenovec is] a very convenient dosing schedule, and it's a very efficacious treatment," says Ravi D. Chauhan, MD, FACS.

Looking forward, Meeks said he sees nadofaragene firadenovec as a promising addition to the NMIBC treatment landscape.